Harel Insurance Investments & Financial Services Ltd. increased its stake in Mediwound Ltd (NASDAQ:MDWD) by 5,084.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 754,434 shares of the biopharmaceutical company’s stock after acquiring an additional 739,882 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Mediwound were worth $3,357,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. lifted its position in Mediwound by 9.5% in the third quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,220,972 shares of the biopharmaceutical company’s stock worth $11,882,000 after buying an additional 192,860 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in Mediwound in the third quarter worth $2,140,000. Nationwide Fund Advisors bought a new stake in Mediwound in the third quarter worth $1,538,000. Finally, Wells Fargo & Company MN lifted its position in Mediwound by 23.5% in the second quarter. Wells Fargo & Company MN now owns 65,763 shares of the biopharmaceutical company’s stock worth $447,000 after buying an additional 12,522 shares during the last quarter. Institutional investors own 29.46% of the company’s stock.
MDWD has been the subject of a number of analyst reports. Oppenheimer set a $10.00 price target on Mediwound and gave the stock a “buy” rating in a research report on Friday, December 8th. SunTrust Banks set a $9.00 price target on Mediwound and gave the stock a “buy” rating in a research report on Thursday, November 16th. Zacks Investment Research downgraded Mediwound from a “buy” rating to a “hold” rating in a research report on Tuesday, November 21st. Finally, ValuEngine upgraded Mediwound from a “strong sell” rating to a “sell” rating in a research report on Saturday, November 25th. Two analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $9.13.
Mediwound (NASDAQ:MDWD) last released its earnings results on Thursday, November 16th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.03. Mediwound had a negative return on equity of 246.58% and a negative net margin of 904.26%. equities research analysts predict that Mediwound Ltd will post -1.06 EPS for the current year.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Want to see what other hedge funds are holding MDWD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mediwound Ltd (NASDAQ:MDWD).
Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.